Pharmacokinetic, Safety, Pharmacodynamic, and Immunogenicity Assessment of LT-01 vs. EU-Approved Omalizumab in Allergic Asthma, Rhinosinusitis, and Urticaria

The primary objective of this study is to conduct a **comparative assessment** of the pharmacokinetics, safety, pharmacodynamics, and immunogenicity of LT-01, an omalizumab biosimilar candidate, in comparison to the EU-approved Xolair® lyophilized powder for subcutaneous injection. This evaluation is conducted in healthy subjects to determine the potential equivalence of LT-01 to the reference product. The clinical relevance of this study lies in its potential to provide an alternative treatment option for conditions such as **allergic asthma**, **chronic rhinosinusitis with nasal polyps**, and **chronic spontaneous urticaria**, which are currently managed with omalizumab. The study does not specify any secondary objectives.

The clinical trial involves a total of **60 participants** diagnosed with **allergic asthma**, **chronic rhinosinusitis with nasal polyps**, or **chronic spontaneous urticaria**. The study population includes both male and female subjects, with an age range of 18 to 65 years. Participants were selected based on their diagnosis of the specified medical conditions, and the trial does not include any vulnerable populations. The general health status of the participants is not specified, nor are there any particular lifestyle considerations such as diet or physical activity mentioned. The sponsor has not provided detailed information regarding the principal inclusion or exclusion criteria for this study.

The clinical trial is designed as a **randomized**, **double-blind**, parallel, and controlled study to evaluate the pharmacokinetics, safety, pharmacodynamics, and immunogenicity of LT-01, an omalizumab biosimilar candidate, compared to the EU-approved Xolair® in healthy subjects. The trial will focus on conditions such as **allergic asthma**, **chronic rhinosinusitis with nasal polyps**, and **chronic spontaneous urticaria**. The estimated recruitment start date is December 2, 2024, with an anticipated end date of July 31, 2025, indicating a total trial duration of approximately eight months.

Participants will undergo a series of study visits, beginning with an inclusion (screening) visit to assess eligibility based on predefined criteria. Following successful screening, participants will be randomized to receive either the test or reference product. Subsequent visits will be scheduled to monitor the pharmacokinetic and pharmacodynamic responses, as well as to assess safety and immunogenicity. These follow-up visits will occur at regular intervals throughout the study period. The end-of-study visit will conclude the trial, where final assessments will be conducted to gather comprehensive data on the study endpoints.

The expected length of participant involvement will span the entire trial duration, from the initial screening to the end-of-study visit. Conditions that may lead to early termination from the study include adverse events, non-compliance with study procedures, or withdrawal of consent by the participant. The trial is structured to ensure rigorous data collection and analysis, adhering to the highest standards of clinical research methodology.

The clinical trial documentation does not provide specific details regarding the **experimental medication** used in the study. Information such as the name, pharmaceutical form, dosage, route, and frequency of administration is not available. Additionally, there is no data on whether the medication is a **paediatric formulation** or if it is classified as an **orphan drug**. The maximum daily dose, total dose, and treatment period are also unspecified.

Details about any **non-experimental treatments** used in the study, such as standard-of-care therapy, placebo, or comparator treatment, are not provided. There is no information on additional relevant aspects of drug administration, dosing schedules, or participant compliance monitoring. The absence of this data limits the ability to describe the treatments comprehensively.

The clinical trial is designed to assess efficacy in a Phase 2 study. The trial is scheduled to commence recruitment on December 2, 2024, with an estimated completion date of July 31, 2025. The efficacy assessment will be conducted through a series of pre-defined parameters, although specific endpoints and methods for measuring efficacy are not detailed in the provided data. The trial will follow a structured timeline to ensure systematic data collection and analysis, adhering to the standards expected in clinical research. The focus will be on evaluating the therapeutic impact of the intervention under investigation, with the aim of determining its potential benefits in the targeted medical condition. The trial will be conducted in accordance with regulatory guidelines to ensure the integrity and reliability of the efficacy data collected.